Back to Journals » OncoTargets and Therapy » Volume 12

Epigenetic mechanism and target therapy of UHRF1 protein complex in malignancies

Authors Xue B, Zhao J, Feng P, Xing J, Wu H, Li Y

Received 25 October 2018

Accepted for publication 10 December 2018

Published 11 January 2019 Volume 2019:12 Pages 549—559

DOI https://doi.org/10.2147/OTT.S192234

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 2

Editor who approved publication: Dr Sanjeev Srivastava


Video abstract presented by Busheng Xue.

Views: 37

Busheng Xue,1 Jiansong Zhao,1 Penghui Feng,2 Jia Xing,3 Hongliang Wu,1 Yan Li1

1Department of Spine and Joint Surgery, Shengjing Hospital, China Medical University, Shenyang, People’s Republic of China; 2Department of Obstetrics and Gynecology-Reproductive Medical Center, Shengjing Hospital, China Medical University, Shenyang, People’s Republic of China; 3Department of Histology and Embryology, Basic Medicine College, China Medical University, Shenyang, People’s Republic of China

Abstract:
Ubiquitin-like with plant homeodomain and really interesting new gene finger domains 1 (UHRF1) functions as an epigenetic regulator recruiting PCNA, DNMT1, histone deacetylase 1, G9a, SuV39H, herpes virus-associated ubiquitin-specific protease, and Tat-interactive protein by multiple corresponding domains of DNA and H3 to maintain DNA methylation and histone modifications. Overexpression of UHRF1 has been found as a potential biomarker in various cancers resulting in either DNA hypermethylation or global DNA hypomethylation, which participates in the occurrence, progression, and invasion of cancer. The role of UHRF1 in the reciprocal interaction between DNA methylation and histone modifications, the dynamic structural transformation of UHRF1 protein within epigenetic code replication machinery in epigenetic regulations, as well as modifications during cell cycle and chemotherapy targeting UHRF1 are evaluated in this study.

Keywords: UHRF1 protein complex, epigenetic modification, ICBP90

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]